Trifluoroacetic acid → methyl 4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-3a-(2-(pyridazin-3-ylamino)ethylamino)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoate

Beteiligte Stoffe

Reaktionsschritte

The title compound was prepared following a similar procedure as described for the synthesis of 4-((1R,3aS,5aR,5bR,7aR,11aS,11bR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-3a-(2-(6-methylpyridazin-3-ylamino)ethylamino)-1-(prop-1-en-2-yl)-2,3,3a,4,5,5a,5b,6,7,7a,8,11,11a,11b,12,13,13a,13b-octadecahydro-1H-cyclopenta[a]chrysen-9-yl)benzoic acid, except 3-chloropyridazine (0.011 g, 0.100 mmol) was used in place of 3-bromo-6-methylpyridazine. Purification of the crude mixture by reverse phase preparative HPLC using Prep HPLC Method 9 gave the title compound as a white glassy solid (4.9 mg, 6.0% yield) bis TFA salt. LCMS: m/e 665.5 (M+H)+, 2.40 min (method 11).

Herkunft & Nachweise